logo
FDA Commissioner Dr. Marty Makary tells 'The Hill' on NewsNation what is next for the MAHA movement

FDA Commissioner Dr. Marty Makary tells 'The Hill' on NewsNation what is next for the MAHA movement

The Hill23-05-2025

FDA Commissioner Dr. Marty Makary joins host Blake Burman to discuss the Trump administration's newly released "Make America Healthy Again" (MAHA) report. Makary asserts that the campaign's goal is to get parents and others to pay attention to some of the environmental factors that their research links to chronic health conditions in the U.S.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Murdoch's Paper Unloads on RFK Jr. Over Axing Vaccine Board
Murdoch's Paper Unloads on RFK Jr. Over Axing Vaccine Board

Yahoo

time14 minutes ago

  • Yahoo

Murdoch's Paper Unloads on RFK Jr. Over Axing Vaccine Board

A Rupert Murdoch-owned paper ripped into Robert F. Kennedy Jr. on Tuesday for gutting the nation's top vaccine advisory panel. The Wall Street Journal published a scathing op-ed a day after Kennedy, a longtime vaccine skeptic, announced the firing spree at the Advisory Committee on Immunization Practices (ACIP) in the paper itself. The ACIP reports to the Centers for Disease Control and Prevention (CDC) on vaccine efficacy. The Secretary of Health and Human Services said he was 'retiring' all 17 members of the advisory committee on vaccines in a 'bold step' to help restore 'public trust.' The move raised alarm bells at a time when health experts fear vaccine skepticism is fueling the nation's largest measles outbreak in around 25 years. 'Most of ACIP's members have received substantial funding from pharmaceutical companies, including those marketing vaccines,' Kennedy wrote, hinting at a plot to push vaccines on Americans. Murdoch's editorial board hit back: 'Mr. Kennedy's beef seems to be that the committee's members know something about vaccines and may have been involved in their research and development.' 'How does he define 'substantial'?' the board asked. The board noted that trial doctors get small payments, typically less than their salaries, from vaccine makers to assist with clinical trials. But 'these trials are double-blinded, meaning doctors don't know which volunteers receive the vaccine or placebo so there's no financial incentive to tilt the data in favor of manufacturers,' the board said. Any conflicts of interest among the committee were also 'honestly handled,' the board said. Kennedy said in a separate announcement that 'a clean sweep is necessary to reestablish public confidence in vaccine science.' 'ACIP new members will prioritize public health and evidence-based medicine. The Committee will no longer function as a rubber stamp for industry profit-taking agendas,' he added. Since joining the Trump administration in January, Kennedy, who is leading the Trump administration's 'Make America Healthy Again' initiative has doubled down on conspiracy theories around shots, including that the measles jab contain 'aborted fetus debris.' 'The MMR vaccine contains millions of particles that are derived from fetal tissue, millions of fragments of human DNA from aborted fetuses,' Kennedy told NBC News' Tom Llamas last month. Kennedy was referring to the combined Measles, Mumps and Rubella vaccine. Vaccines do not contain aborted fetuses, fetal cells, fetal DNA, or fetal debris, according to the Children's Hospital of Philadelphia. The rubella component of the vaccine is developed from a fetal cell line known as WI-38 that originally came from the lung tissue of an elective abortion performed more than five decades ago. No new fetal issue has been used since, and cells used today are thousands of times removed from the original source. Health experts are alarmed by Kennedy's suggestions that the measles jab is unsafe, a claim which contradicts decades of research from the Centers for Disease Control and Prevention. The World Health Organization declared measles eliminated from the United States in 2000 due to the success of vaccination efforts. International travel and growing vaccine hesitancy are thought to be behind its resurgence. The American Medical Association has said Kennedy's decision to gut ACIP undermines 'trust and upends a transparent process that has saved countless lives.' Kennedy wrote in his op-ed for the Journal that ACIP's new members 'won't directly work for the vaccine industry.' 'They will exercise independent judgment, refuse to serve as a rubber stamp, and foster a culture of critical inquiry—unafraid to ask hard questions.' ACIP is set to hold its next meeting on June 25 at the CDC's headquarters.

RFK Jr. Bombarded Bill Nye With Endless Anti-Vax Text Screeds
RFK Jr. Bombarded Bill Nye With Endless Anti-Vax Text Screeds

Yahoo

timean hour ago

  • Yahoo

RFK Jr. Bombarded Bill Nye With Endless Anti-Vax Text Screeds

Robert F. Kennedy Jr. sent a flood of texts to Bill Nye trying to convince the beloved 'Science Guy' of his anti-vax claims. The old text chain, sent before Kennedy became Donald Trump's health secretary, was revealed by Nye during a Men's Health profile of the children's television presenter. The barrage of messages from the prominent vaccine skeptic, which the magazine described as 'miles and miles of texts,' contained numerous links to articles and websites peddling vaccine-autism conspiracies that Nye said he paid no real attention to. 'Just no self-awareness,' Nye said. 'And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection. I wrote him back and said, 'Okay, I'll read your book. I think you've confused causation with correlation. Your friend, Bill.'' The stream of messages did not end there, Nye said, even after he told Kennedy, 'Okay, no more texts.' 'He started again! So I cut him off,' Nye said. 'He does not have good judgment. He is not suited for this job.' The Department of Health and Human Services did not immediately respond to a request for comment from the Daily Beast. Kennedy has led a full-blown assault on vaccines as part of the Trump administration's campaign to restore public 'trust' in the lifesaving shots. That includes the shock move to fire all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP), an expert panel that evaluates vaccine safety and efficacy. All had been appointed under the Biden administration. In a Wall Street Journal op-ed, Kennedy said vaccines had become a 'divisive issue in American politics' and that public confidence in the health agencies that provide them is 'waning.' Nye said the increase in vaccine skepticism, which soared amid the COVID-19 pandemic, is having real life negative consequences on people's lives. That includes the reaction to a measles outbreak in Texas that primarily hit unvaccinated individuals in the Mennonite community. 'It was a religious sect with historically low vaccination rates. And the argument from the other side is: They have rights not to get vaccinated. No, you don't,' a frustrated Nye said. 'Unvaccinated people can, and usually do, spread a disease. And that's why we have these rules, for public health! It's not arbitrary. It's not about your rights. It's about my rights, people.' Nye didn't hold back on Kennedy's bizarre public stunts either—like chugging raw milk with health influencer Dr. Paul Saladino to promote the Trump administration's initially error-riddled Make America Healthy Again report on childhood illness. 'And then this thing where people want to drink raw milk. No, you don't,' Nye said. 'This is very well understood! Louis Pasteur! You guyyys! What is happening?' For more, listen to Bill Nye the Science Guy on The Last Laugh podcast.

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

timean hour ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store